SequelSEC

Royalty Pharma plc RPRX

Pharmaceutical Preparations · CIK 0001802768 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$2.38B
Fiscal year ended 2025-12-31
Operating income
$1.56B
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

Royalty Pharma plc (RPRX) reported revenue of $2.38B and net income of $770.95M for the fiscal year ended 2025-12-31. This page shows 8 annual periods of income statement, balance sheet and cash flow figures normalized from Royalty Pharma plc’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Royalty Pharma plc income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Revenue$2.38B$2.26B$2.35B$2.24B$2.29B$2.12B$1.81B$1.79B
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income$1.56B$1.29B$1.49B$307.06M$1.43B$1.60B$2.62B$1.36B
Net income$770.95M$858.98M$1.13B$42.83M$619.73M$975.04M$2.35B$1.38B
Research & development$452.00M$2.00M$52.00M$177.11M$200.08M$26.29M$83.04M$392.61M
Weighted-average diluted sharesshares 564.46Mshares 594.11Mshares 602.90Mshares 437.97Mshares 414.80Mshares 375.46MUnavailableUnavailable
Pretax income$1.32B$1.33B$1.70B$230.06M$1.24B$1.70B$2.46B$1.52B
Income tax expense$0$0$0$0$0$0$0$0
Diluted EPS$1.78$1.91$2.53$0.10$1.49$1.32UnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$573.48M$236.67M$249.75M$227.30M$182.83M$181.72M$103.44M$61.91M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Royalty Pharma plc balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Cash & equivalents$618.70M$929.03M$477.01M$1.71B$1.54B$1.01B$246.20MUnavailable
Total assets$19.62B$18.22B$16.38B$16.81B$17.52B$16.02B$12.45BUnavailable
Current assets$1.53B$1.80B$1.27B$2.55B$2.88B$2.70B$832.07MUnavailable
Total liabilities$9.91B$7.88B$6.30B$7.29B$7.27B$6.12B$6.31BUnavailable
Current liabilities$636.21M$1.25B$161.38M$1.17B$171.25M$307.89M$333.42MUnavailable
Total equity incl. NCI$9.71B$10.34B$10.08B$9.53B$10.25B$9.90B$6.14B$4.55B
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Goodwill$924.63M$0UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt$8.57B$6.61B$6.14B$6.12B$7.10B$5.82B$5.96BUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Cash flow

Royalty Pharma plc cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Operating cash flow$2.49B$2.77B$2.99B$2.14B$2.02B$2.03B$1.67B$1.62B
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flow-$1.61B-$2.68B-$2.07B-$1.03B-$1.87B-$2.76B-$2.15B$303.42M
Financing cash flow-$1.19B$361.14M-$2.15B-$944.86M$385.11M$1.49B-$1.19B-$1.38B
Net change in cash-$310.33M$452.02M-$1.23B$169.70M$532.37M$762.48M-$1.68B$542.64M
Stock-based compensation$289.89M$2.34M$2.36M$2.17M$2.44M$5.43M$0$0
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchases$1.23B$229.65M$304.76M$0$0$0$4.27M$0
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Royalty Pharma plc derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin65.6%57.1%63.4%13.7%62.5%75.2%144.6%76.0%
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenue12.2%0.1%0.1%0.1%0.1%0.3%0.0%0.0%
Current ratio2.40x1.44x7.90x2.19x16.81x8.76x2.50xUnavailable
Revenue YoY growth5.1%-3.9%5.2%-2.3%7.9%17.0%1.1%Unavailable
Net margin32.4%37.9%48.2%1.9%27.1%45.9%129.4%76.8%
R&D / revenue19.0%0.1%2.2%7.9%8.7%1.2%4.6%21.9%
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equity0.88xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open RPRX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-05View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-K · Filed 2026-02-11View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-06View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.